Author Archives

TG therapeutics announces publication of clinical data from a Phase 1/2 trial of TG-1101 in the British Journal of Haematology

Company announced the publication of clinical data from a Phase 1/2 trial of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkins Lymphoma (NHL) or Chrionic Lymphocytic Leukemia (CLL) previously exposed to rituximab. The data demonstrates single agent TG-1101 to be well tolerated with the most common adverse event observed […]

AUPH: Acquiring more shares of AUPH

To All, Just looking for some feedback from everyone. I was considering purchasing more Aurinia to possibly take advantage of the short term catalyst which would be the upcoming release of secondary data from their Phase IIb Aura trial to help recoup losses from the FDA debacle of RGLS. Maybe some have already done so. […]

Tg Therapeutics

To All, I noticed that Michael Weiss, CEO of TG Therapeutics reduced his total share count considerably in 2016. He went from owning 4.5 million shares down to 1.1 million. Maybe he had to unload them by a certain date, I am not that familiar with shares owned by insiders. Just wanted to bring it […]

Recent Author Comments

On Can you Earn Huge Royalties from the "Fountain of Youth" Drug Marc Lichtenfeld says was Discovered on Easter Island?
Travis, I stuck with you!!!! Travis, I remember seeing a substantial list of investments which could have been be your portfolio or just a list of equities with a better chance to appreciate. Would you mind sharing that list again and if it is displayed s[...]
On Biotech Discussion... continued
Cleveland, Someone on this site commented about a conference call yesterday, I don't know if it is true or not. I tried calling the old replay number but it asked for a access code, never asked for one before, I don't have it so I was denied access to the [...]
On Biotech Discussion... continued
Thomas, Great piece on cancer research, is there a publicly traded company that we could invest in using this approach?[...]
On The Twelve Biotechs of Christmas 2018: Balthasar
VTGN, Pgathua, Excellent article reagrding Vistagen but I have a question maybe you can help me with, is the patent for the "mechanism of action". I am not a scholar by any means but does this cover the way AV-101 is manufactured and does it cover the age[...]
On The Twelve Biotechs of Christmas 2018: Balthasar
SNDX To All, In the last 30 minutes or so, Syndax has gone up from 9.20ish to 9.80 or so and volume hs increased dramatically!![...]
On What the heck is "NanoCrystal Electricity?" Will it "Magically Power Everything" and "pay out 78 times your money?"
fanfare, knowledge is power[...]
On Dr. KSS Posts from Biotech Showcase 2018, San Francisco
Hey Doc, DFFN- I was reviewing the members on the Scientific Advisory Board of Diffusion Pharna and it is like a list of Who's Who. Their credentials are just staggering. With the wealth of knowledge and experience that these gentlemen have, how do you go [...]
On Dispelling Certain Aurinia ($AUPH) Rumors
kirzli, sndx-I share your concern, but I hope that entinostat will have better results with advanced hormone receptor positive breast cancer. I am buried in the stock and I am going to stick it out.[...]
On Dispelling Certain Aurinia ($AUPH) Rumors
Doc Apto-I also saw that document on Friday as well, and I thought the same, it was unclear.[...]
On Dispelling Certain Aurinia ($AUPH) Rumors
SoGi, APTO ow as well- The bid is 1.87 and the ask is 1.95. Thde bid is .12 cents higher in premarket now. I utilize etrade, for some reason they asre always behind the news. I should have held the massive amount of shares I had. Best of luck to all of us.[...]
On Special Update from $ARTH CEO Norchi
SoGiAm, Thanks for passing on the article by Dr. Gottlieb. It appears to me that gene therapy may be a hot topic in 2018 and beyond. Just curious, are there any gene therapy companies that you like or possibly have the potential of success. Maybe gene ther[...]
On Microblog: Prime System
BABY, More like 40%-45%[...]
On Special Comment: Update from $ARTH CEO Terrence Norchi, MD, MBA
Doc, VTGN You had mentioned on the conference call on Friday that in your opinion, Vistagen had been unfairly punished by the market. What happened to Vistagen that the marekt punished them for. I dont remember if you had given us the reason why, if there[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
To All, APTO Greg Chow and Dr. Rice have treated me like I am an institutional investor and made me feel welcomed and respected, you can't put a price on that and they have my full support regardless of the outcome. As I mentioned in an earlier post, Dr. R[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
zimmy,, In my opinion, if you don't see dilution, due to the fact that dilution goes hand in hand with raising capital, is more of an issue than not. And also, the amount of shares that are currently available for Aptose are only 20 million plus which is s[...]
On Tear Sheet: CohBar Inc. ($CWBR)
Doc, Dr. Rice is the only CEO to ever personally respond to one of my questions, that goes along with way with me and both Greg and Dr. Rice have my full support. Doc, those guys are good people and thanks again for the recommendation. I have no doubt that[...]
On Tear Sheet: CohBar Inc. ($CWBR)
mmccrum, Everyone here praises Dr. KSS and rightfully so, but we hardly ever thank Cleveland for what he brings to the table, which in my opinion, is just as important as the science. Look what happened to Windtree due to their mishandling of funds. Thank [...]
On Tear Sheet: CohBar Inc. ($CWBR)
ARTH Exactly Tanglewood, seen it to many times, puch the stock down 20-30% then shortly after news is released[...]
On Tear Sheet: CohBar Inc. ($CWBR)
ARTH, I was watching the activity on ARTH, they pushed the price of the shares down to the 50 cent range and scooped up over 200,000 shares and then it went back up to 55 cents on the ask all within 10 seconds, UNBELIEVABLE. Either 1 of two things 1) short[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
ARTH What takes so long for the FDA to respond to their NDA, they did submit one.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch